C
Christian T. Ruff
Researcher at Brigham and Women's Hospital
Publications - 185
Citations - 11954
Christian T. Ruff is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Warfarin & Atrial fibrillation. The author has an hindex of 43, co-authored 156 publications receiving 9521 citations. Previous affiliations of Christian T. Ruff include Durham University & Harvard University.
Papers
More filters
Journal ArticleDOI
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff,Robert P. Giugliano,Eugene Braunwald,Elaine B. Hoffman,Naveen Deenadayalu,Michael D. Ezekowitz,A. John Camm,Jeffrey I. Weitz,Basil S. Lewis,Alexander Parkhomenko,Takeshi Yamashita,Elliott M. Antman +11 more
TL;DR: A prespecified meta-analysis of all 71,683 participants included in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials offered clinicians a more comprehensive picture of the new oral anticoagulants as a therapeutic option to reduce the risk of stroke in this patient population.
Journal ArticleDOI
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report
Gregory Y.H. Lip,Amitava Banerjee,Giuseppe Boriani,Chern En Chiang,Ramiz Fargo,Ben Freedman,Deirdre A. Lane,Christian T. Ruff,Mintu P. Turakhia,David J. Werring,Sheena Patel,Lisa K. Moores +11 more
TL;DR: Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with AF with ≥1 non‐sex CHA2DS2‐VASc stroke risk factor(s), and stroke prevention (ie, oral antICOagulation therapy) is the next step.
Journal ArticleDOI
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
Christian T. Ruff,Robert P. Giugliano,Elliott M. Antman,Sharon Crugnale,Tomas S. Bocanegra,Michele Mercuri,James J. Hanyok,Indravadan Patel,Minggao Shi,Dan Salazar,Carolyn H. McCabe,Eugene Braunwald +11 more
TL;DR: In this paper, a phase 3 comparison of the novel oral factor Xa inhibitor edoxaban to warfarin for the prevention of thromboembolism in patients with atrial fibrillation was conducted.
Journal ArticleDOI
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri Toda Kato,Michael G. Silverman,Ofri Mosenzon,Thomas A Zelniker,Avivit Cahn,Remo H.M. Furtado,Julia F Kuder,Sabina A. Murphy,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P.H. Wilding,Marc P. Bonaca,Christian T. Ruff,Akshay S. Desai,Shinya Goto,Peter A. Johansson,Ingrid Gause-Nilsson,Per Johanson,Anna Maria Langkilde,Itamar Raz,Marc S. Sabatine,Stephen D. Wiviott +22 more
TL;DR: In the first sodium-glucose cotransporter 2 inhibitor cardiovascular outcome trial to evaluate patients with type 2 diabetes mellitus stratified by EF, it is found that dapagliflozin reduced HHF in patients with and without HFrEF and reduced cardiovascular death and all-cause mortality in Patients with HFr EF.
Journal ArticleDOI
Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease
Jessica L. Mega,Willibald Hochholzer,Andrew L. Frelinger,Michael J. Kluk,Dominick J. Angiolillo,Dean J. Kereiakes,Steven Isserman,William J. Rogers,Christian T. Ruff,Charles F. Contant,Michael J. Pencina,Benjamin M. Scirica,Janina A. Longtine,Alan D. Michelson,Marc S. Sabatine +14 more
TL;DR: Among patients with stable cardiovascular disease, tripling the maintenance dose of clopidogrel to 225 mg daily in CYP2C19*2 heterozygotes achieved levels of platelet reactivity similar to that seen with the standard 75-mg dose in noncarriers.